Abstract:Half-sandwich pseudo-octahedral pentamethylcyclopentadienyl IrIII complexes of the type [(η5-Cpx)Ir(C^C)Cl]PF6, where Cpx is pentamethylcyclopentadienyl (Cp*), or its phenyl (Cpxph = C5Me4C6H5) or biphenyl (Cpxbiph = C5Me4C6H4C6H5) derivatives, and the C^C-chelating ligands are different N-heterocyclic carbene (NHC) ligands, have been synthesized and characterized. Three X-ray crystal structures have been determined. Except for Cp* complex 1A, the other eleven complexes 1B-4C all showed potent cytotoxicity, with IC50 values ranging from 2.9 to 46.3 μM toward HeLa human cervical cancer cells. The potency toward HeLa cells increased with additional phenyl substitution on Cp*: Cpxbiph > Cpxph > Cp*, and increased with the size of chain substitution on the C^C-ligand in the order: ph > butyl > ethyl > methyl. Complex [(η5-C5Me4C6H4C6H5)Ir(L4)Cl]PF6 (4C) displayed the highest potency, and was about 3 times more active than the clinical platinum drug cisplatin. Complexes 1A-4C all undergo hydrolysis and their kinetics was studied. DNA binding appears not to be the major mechanism of action. The ability of these iridium complexes to catalyze hydride transfer from the coenzyme NADH to NAD+ was studied. Complexes [(η5-C5Me4C6H4C6H5)Ir(L2)Cl]PF6 (2C) and [(η5-C5Me4C6H4C6H5)Ir(L3)Cl]PF6 (3C) cause cell apoptosis and arrest the cell cycle at the G1 phase and G2/M phase when HeLa cancer cells are treated with different IC50 concentrations of the complexes, and increase the amount of reactive oxygen species (ROS) dramatically, which appears to contribute to the anticancer activity. This class of organometallic Ir complexes has unusual features worthy of further exploration in the design of novel anticancer drugs.

Ferrocene-modified Half-Sandwich Iridium(iii) and Ruthenium(ii) Propionylhydrazone Complexes and Anticancer Application

Configurationally regulated half-sandwich iridium(III)-ferrocene heteronuclear metal complexes: Potential anticancer agents

Anticancer application of half-sandwich iridium(III) ferrocene-thiosemicarbazide Schiff base complexes

Mitochondrial Targeting Half-Sandwich Iridium(iii) and Ruthenium(ii) Dppf Complexes and in Vitro Anticancer Assay

Half-sandwich Iridium N-heterocyclic Carbene Anticancer Complexes

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Half-Sandwich Iridium(III), Rhodium(III), and Ruthenium(II) Complexes Chelating Hybrid sp 2 -N/sp 3 -N Donor Ligands to Achieve Improved Anticancer Selectivity

Effects of structurally varied fluorescent half-sandwich iridium(III) Schiff base complexes on A549 cell line

Cationic N,S-chelate Half-Sandwich Iridium Complexes: Synthesis, Characterization, Anticancer and Antiplasmodial Activity.

Iminoamido chelated iridium(III) and ruthenium(II) anticancer complexes with mitochondria-targeting ability and potential to overcome cisplatin resistance

Lysosomal Targeted Cyclometallic Iridium(III) Salicylaldehyde-Coumarin Schiff Base Complexes and Anticancer Application

Lysosomal Targeted Cyclometallic Iridium(Ⅲ) Salicylaldehyde-Coumarin Schiff Base Complexes and Anticancer Application

Increasing Anticancer Activity with Phosphine Ligation in Zwitterionic Half-Sandwich Iridium(III), Rhodium(III), and Ruthenium(II) Complexes

Synthesis, Subcellular Localization and Anticancer Mechanism Studies of Unsymmetrical Iridium(III) Complexes

Novel ferrocene cyclopalladated compounds: Synthesis, and in‐vitro antitumor activity study

In Vitro and In Vivo Antitumor Assay of Mitochondrially Targeted Fluorescent Half-Sandwich Iridium(III) Pyridine Complexes

A novel ferrocene-palladium metal complex: synthesis, single crystal structure, in vitro cytotoxicity study and molecular docking

Lysosome-targeted Chemotherapeutics: Anticancer Mechanism of N-heterocyclic Carbene Iridium(iii) Complex.

Preparation and Bioactivity of Iridium(III) Phenanthroline Complexes with Halide Ions and Pyridine Leaving Groups

Recent Advances in Ruthenium and Platinum Based Supramolecular Coordination Complexes for Antitumor Therapy

New ferrocene cyclopalladated compounds: synthesis, X-ray single crystal structure and in vitro anticancer activity study